Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387

EMBO Journal

Volumn 36, Issue 2, 2017, Pages 202-212

  Wang, Yuxin ^a,b   Nan, Jing ^b,c   Willard, Belinda ^b   Wang, Xin ^b   Yang, Jinbo ^a,c   Stark, George R ^b  

^a Laboratory for Marine Science and Technology   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

^c LANZHOU UNIVERSITY   (China)

Author keywords

negative regulation; STAT2; T387 phosphorylation; type I interferon

Indexed keywords

BETA INTERFERON; CYCLIN DEPENDENT KINASE; DNA; GLUCOCORTICOID; INTERFERON; INTERFERON STIMULATED GENE FACTOR 3; M PROTEIN; PROTEIN; STAT PROTEIN; T387 PROTEIN; UNCLASSIFIED DRUG; STAT2 PROTEIN;

ARTICLE; BREAST EPITHELIUM CELL; CANCER GROWTH; CELL SPECIFICITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA BINDING; FIBROBLAST CULTURE; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MCF-7 CELL LINE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; VIRUS REPLICATION; BIOLOGICAL MODEL; CELL LINE; METABOLISM; PHOSPHORYLATION; PROTEIN PROCESSING;

CELL LINE; HUMANS; INTERFERON-BETA; INTERFERON-STIMULATED GENE FACTOR 3; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; STAT2 TRANSCRIPTION FACTOR;

EID: 85003534277     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.15252/embj.201694834     Document Type: Article

References (29)

1. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discovery 14: 130–146
2. Asmana Ningrum R (2014) Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo) 2014: 970315
3. Banninger G, Reich NC (2004) STAT2 nuclear trafficking. J Biol Chem 279: 39199–39206
4. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, Livingston DM (1996) Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 383: 344–347
5. Blaho JA, Morton ER, Yedowitz JC (2005) Herpes simplex virus: propagation, quantification, and storage. Curr Protocol Microbiol 14E.1.1–14E.1.23
6. Blaszczyk K, Olejnik A, Nowicka H, Ozgyin L, Chen YL, Chmielewski S, Kostyrko K, Wesoly J, Balint BL, Lee CK, Bluyssen HA (2015) STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. Biochem J 466: 511–524
7. Bluyssen HA, Levy DE (1997) Stat2 is a transcriptional activator that requires sequence-specific contacts provided by stat1 and p48 for stable interaction with DNA. J Biol Chem 272: 4600–4605
8. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S, Lee PP (2009) Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA 106: 9010–9015
9. Dasgupta M, Dermawan JK, Willard B, Stark GR (2015) STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc Natl Acad Sci USA 112: 3985–3990
10. Decker T, Kovarik P (2000) Serine phosphorylation of STATs. Oncogene 19: 2628–2637
11. Fensterl V, Wetzel JL, Sen GC (2014) Interferon-induced protein Ifit2 protects mice from infection of the peripheral nervous system by vesicular stomatitis virus. J Virol 88: 10303–10311
12. Leung S, Qureshi SA, Kerr IM, Darnell JE Jr, Stark GR (1995) Role of STAT2 in the alpha interferon signaling pathway. Mol Cell Biol 15: 1312–1317
13. Li X, Leung S, Qureshi S, Darnell JE Jr, Stark GR (1996) Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha. J Biol Chem 271: 5790–5794
14. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408
15. Mao X, Ren Z, Parker GN, Sondermann H, Pastorello MA, Wang W, McMurray JS, Demeler B, Darnell JE Jr, Chen X (2005) Structural bases of unphosphorylated STAT1 association and receptor binding. Mol Cell 17: 761–771
16. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A (2015) Type I interferons in infectious disease. Nat Rev Immunol 15: 87–103
17. Mertens C, Zhong M, Krishnaraj R, Zou W, Chen X, Darnell JE Jr (2006) Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. Genes Dev 20: 3372–3381
18. Park C, Li S, Cha E, Schindler C (2000) Immune response in Stat2 knockout mice. Immunity 13: 795–804
19. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5: 375–386
20. Romerio F, Riva A, Zella D (2000) Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism. Br J Cancer 83: 532–538
21. Schang LM, St Vincent MR, Lacasse JJ (2006) Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antiviral Chem Chemother 17: 293–320
22. Steen HC, Nogusa S, Thapa RJ, Basagoudanavar SH, Gill AL, Merali S, Barrero CA, Balachandran S, Gamero AM (2013) Identification of STAT2 serine 287 as a novel regulatory phosphorylation site in type I interferon-induced cellular responses. J Biol Chem 288: 747–758
23. Tang X, Gao JS, Guan YJ, McLane KE, Yuan ZL, Ramratnam B, Chin YE (2007) Acetylation-dependent signal transduction for type I interferon receptor. Cell 131: 93–105
24. Walter MR, Bordens R, Nagabhushan TL, Williams BR, Herberman RB, Dinarello CA, Borden EC, Trotta PP, Pestka S, Pfeffer LM (1998) Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon. Cancer Biother Radiopharm 13: 143–154
25. Yamamoto M, Onogi H, Kii I, Yoshida S, Iida K, Sakai H, Abe M, Tsubota T, Ito N, Hosoya T, Hagiwara M (2014) CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses. J Clin Invest 124: 3479–3488
26. Yan N, Chen ZJ (2012) Intrinsic antiviral immunity. Nat Immunol 13: 214–222
27. Yang J, Huang J, Dasgupta M, Sears N, Miyagi M, Wang B, Chance MR, Chen X, Du Y, Wang Y, An L, Wang Q, Lu T, Zhang X, Wang Z, Stark GR (2010) Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci USA 107: 21499–21504
28. Yu Q, Katlinskaya YV, Carbone CJ, Zhao B, Katlinski KV, Zheng H, Guha M, Li N, Chen Q, Yang T, Lengner CJ, Greenberg RA, Johnson FB, Fuchs SY (2015) DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function. Cell Rep 11: 785–797
29. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G (2015) Type I interferons in anticancer immunity. Nat Rev Immunol 15: 405–414